<?xml version="1.0" encoding="UTF-8"?>
<p id="par0470">There are a number of arguments in favour of the acquisition of protective immunity through the use of neutralising antibodies:
 <list list-type="simple" id="lis0060">
  <list-item id="lsti0195">
   <label>•</label>
   <p id="par0475">the disease in its mild form is easily curable (85% of cases);</p>
  </list-item>
  <list-item id="lsti0200">
   <label>•</label>
   <p id="par0480">the absence of recurrence among those cured, as shown by the absence of cases published in France out of hundreds of thousands of declared cases
    <xref rid="fn0115" ref-type="fn">23</xref> ;
   </p>
  </list-item>
  <list-item id="lsti0205">
   <label>•</label>
   <p id="par0485">symptomatic subjects have a good antibody response, the paucisymptomatic forms have a weaker and sometimes delayed response;</p>
  </list-item>
  <list-item id="lsti0210">
   <label>•</label>
   <p id="par0490">recent experimental data in the macaque monkey show that it presents a benign disease, that it responds, like humans, by producing neutralizing antibodies, that it becomes resistant to massive superinfection and is no longer contagious.</p>
  </list-item>
 </list>
</p>
